Visualization of Fibroblast Activation After Myocardial Infarction Using 68Ga-FAPI PET.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
entrez:
3
9
2021
pubmed:
4
9
2021
medline:
16
10
2021
Statut:
ppublish
Résumé
The aim of this retrospective analysis was to examine the pattern of cardiac 68Ga-fibroblast-activation protein-α inhibitor (FAPI) uptake in patients after acute myocardial infarction (AMI) using PET and to investigate its association with results of coronary angiography. We correlated FAPI uptake with biomarkers of myocardial damage including left ventricular function. A cohort of 10 patients with no history of coronary artery disease underwent PET 18 ± 20.6 days after AMI (ST-segment elevation myocardial infarction [n = 5] and non-ST-segment elevation infarction [n = 5]), respectively. SUVmax, SUVmean, and SUVpeak of localized tracer uptake were calculated; tracer uptake volume was reported as fibroblast activation volume (FAV), with imaging data being correlated with clinical parameters. Focal FAPI uptake was observed in all patients. Average uptake at 10 minutes postinjection was 8.9 ± 4.4 (SUVmax), 7.6 ± 4.0 (SUVpeak), and 5.3 ± 2.8 (SUVmean), respectively. Affected myocardium showed a partial to complete match between tracer uptake and confirmed culprit lesion by coronary angiography in 44.4% and 55.6% of patients, respectively. A strong correlation between FAV and peak creatine kinase level (r = 0.90, P < 0.01) and inverse correlation of FAV with left ventricular function (r = -0.69, P < 0.05) was observed. This analysis demonstrates in vivo visualization of fibroblast activation after AMI. The uptake area showed a very good agreement with the affected coronary territory. A strong correlation of the de novo established parameter FAV with left ventricular function and peak creatine kinase was observed. This imaging modality may provide important insights into mechanisms of structural remodeling after AMI at an early stage.
Identifiants
pubmed: 34477601
doi: 10.1097/RLU.0000000000003745
pii: 00003072-202110000-00004
doi:
Substances chimiques
68Ga-FAPI
0
Quinolines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
807-813Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Humeres C, Frangogiannis NG. Fibroblasts in the infarcted, remodeling, and failing heart. JACC Basic Transl Sci . 2019;4:449–467.
Rog-Zielinska EA, Norris RA, Kohl P, et al. The living scar—cardiac fibroblasts and the injured heart. Trends Mol Med . 2016;22:99–114.
Ma Y, Iyer RP, Jung M, et al. Cardiac fibroblast activation post–myocardial infarction: current knowledge gaps. Trends Pharmacol Sci . 2017;38:448–458.
Shinde AV, Frangogiannis NG. Fibroblasts in myocardial infarction: a role in inflammation and repair. J Mol Cell Cardiol . 2014;70:74–82.
Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction—from repair and remodeling to regeneration. Cell Tissue Res . 2016;365:563–581.
Van Hout GP, Arslan F, Pasterkamp G, et al. Targeting danger-associated molecular patterns after myocardial infarction. Expert Opin Ther Targets . 2016;20:223–239.
Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev . 2007;87:1285–1342.
Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation. JACC Clin Electrophysiol . 2017;3:425–435.
Tillmanns J, Hoffmann D, Habbaba Y, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol . 2015;87:194–203.
Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med . 2018;59:1415–1422.
Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation . 2000;101:2981–2988.
Ørn S, Manhenke C, Anand IS, et al. Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction. Am J Cardiol . 2007;99:1109–1114.
Varasteh Z, Mohanta S, Robu S, et al. Molecular imaging of fibroblast activity after myocardial infarction using a 68 Ga-labeled fibroblast activation protein inhibitor, FAPI-04. J Nucl Med . 2019;60:1743–1749.
Stienen S, Rossignol P, Barros A, et al. Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials. Clin Res Cardiol . 2020;109:194–204.
Giesel F, Kratochwil C, Lindner T, et al. FAPI-PET/CT: biodistribution and preliminary dosimetry estimate of two DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med . 2019;60:386–392. 10.2967/jnumed.118.215913.
doi: 10.2967/jnumed.118.215913
Kratochwil C, Flechsig P, Lindner T, et al. 68 Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med . 2019;60:801–805.
Sharma P, Singh SS, Gayana S. Fibroblast activation protein inhibitor PET/CT: a promising molecular imaging tool. Clin Nucl Med . 2021;46:e141–e150.
Zhu W, Guo F, Wang Y, et al. 68 Ga-FAPI-04 accumulation in myocardial infarction in a patient with neuroendocrine carcinoma. Clin Nucl Med . 2020;45:1020–1022.
Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol . 2008;1:62–73.
Almaas VM, Haugaa KH, Strøm EH, et al. Increased amount of interstitial fibrosis predicts ventricular arrhythmias, and is associated with reduced myocardial septal function in patients with obstructive hypertrophic cardiomyopathy. Europace [Internet] . 2013;15:1319–1327.
Giesel FL, Kratochwil C, Lindner T, et al. 68 Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med . 2019;60:386–392.
Law WP, Wang WYS, Moore PT, et al. Cardiac amyloid imaging with 18 F-florbetaben PET: a pilot study. J Nucl Med . 2016;57:1733–1739.
Kircher M, Ihne S, Brumberg J, et al. Detection of cardiac amyloidosis with 18 F-florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur J Nucl Med Mol Imaging . 2019;46:1407–1416.
Dorbala S, Vangala D, Semer J, et al. Imaging cardiac amyloidosis: a pilot study using 18 F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging . 2014;41:1652–1662.
Nekolla SG, Miethaner C, Nguyen N, et al. Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography. Eur J Nucl Med . 1998;25:1313–1321.
Heckmann MB, Reinhardt F, Finke D, et al. Relationship between cardiac fibroblast activation protein activity by positron emission tomography and cardiovascular disease. Circ Cardiovasc Imaging . 2020;13:1–9.
Siebermair J, Köhler MI, Kupusovic J, et al. Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. J Nucl Cardiol . 2020. doi:10.1007/s12350-020-02307-w.
doi: 10.1007/s12350-020-02307-w
Nagaraju CK, Dries E, Popovic N, et al. Global fibroblast activation throughout the left ventricle but localized fibrosis after myocardial infarction. Sci Rep . 2017;7:1–14.
Chia S, Senatore F, Raffel OC, et al. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv . 2008;1:415–423.
Turer AT, Mahaffey KW, Gallup D, et al. Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction. Curr Control Trials Cardiovasc Med . 2005;6:1–11.
Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med . 1996;335:1933–1940.
Tillmanns J, Fraccarollo D, Galuppo P, et al. Changes in concentrations of circulating fibroblast activation protein alpha are associated with myocardial damage in patients with acute ST-elevation MI. Int J Cardiol . Elsevier B.V.; 2017;232:155–159.
Nattel S. How does fibrosis promote atrial fibrillation persistence: in silico findings, clinical observations, and experimental data. Cardiovasc Res . 2016;110:295–297.